MUMBAI: The price of favipiravir has crashed more than 40% in a month and is expected to fall further over the next week, as stiff competition is emerging in the market for supplying the experimental drug indicated for Covid-19 patients with mild-to-moderate symptoms.The Drug Controller General of India has this week given approval to BDR Pharmaceuticals, Optimus Pharma and Cipla to manufacture the raw materials and finished product of the